Navigation Links
Lilly Oncology to Unveil More Than 50 Studies at ASCO 2008
Date:5/1/2008

ALIMTA Lung Cancer Study Highlighting Key Histology Findings to Be Included

in May 15 ASCO Live, Online Presscast

INDIANAPOLIS, May 1 /PRNewswire-FirstCall/ -- Eli Lilly and Company will unveil data from more than 50 studies at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill. from May 30 to June 3, 2008. The company will present the latest research findings on ALIMTA(R) (pemetrexed for injection), GEMZAR(R) (gemcitabine HCl for injection), and enzastaurin, an investigational, oral, targeted therapy. The majority of the studies being presented are findings that support Lilly's leadership in thoracic cancer research.

Of note is a pivotal Phase III study (ASCO Abstract # 8011) that demonstrated a key correlation between lung cancer histology (tissue type), treatment choice and patient outcome. It will be one of the studies featured on Thursday, May 15 in ASCO's live online presscast. The virtual press event will be the first time ASCO has selected researchers to present key abstracts prior to its annual meeting.

"Improved patient outcomes via tailored therapy continues to be our focus and this year's ASCO is no exception," said Richard Gaynor, M.D., Lilly vice president, cancer research and global oncology platform leader. "With Lilly studies focusing on thoracic and breast cancer, among others, this meeting will continue to show our commitment to answering the unmet needs of cancer care."

Key Pemetrexed Abstracts for ASCO 2008:

-- Abstract # 8011: June 2, 2008; 3:00 p.m.

-- Maintenance pemetrexed plus best supportive care (BSC) versus

placebo plus BSC: A phase III study

-- This study will be featured during ASCO presscast on May 15

-- Abstract # 8096: June 1, 2008; 2:00 p.m.

-- Comparison of patient outcomes stratified by histology among

pemetrexed-treated patients with stage IIIB/IV NSCLC in two Phase

II trials

-- Abstract # 8097: June 1, 2008; 2:00 p.m.

-- Resource utilization by non-small cell lung cancer histology:

Results from the randomized, phase III trial of

pemetrexed/cisplatin versus gemcitabine/cisplatin

For more information on Lilly Oncology agents, including full prescribing information, please visit http://www.lillyoncology.com .

(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Lilly Declares Second-Quarter Dividend
2. Lilly to Streamline Indianapolis Manufacturing and Engineering Operations
3. Lilly Adjusts Time of Conference Call for First Quarter 2008 Financial Results Announcement
4. Lilly Sets Date and Conference Call for First Quarter 2008 Financial Results Announcement
5. State of Alaska and Eli Lilly and Company Reach Agreement to Settle Zyprexa Lawsuit
6. Statement from Eli Lilly and Company: Response to Todays New York Times Article, Lilly E-Mail Discussed Off-Label Drug Use
7. Lilly Grants $4.4 Million to the WHO for MDR-TB Program Expansion
8. Newly Labeled Therapies for Neuropathic Pain, Including Drugs From Pfizer and Eli Lilly, Will Drive Growth in the Chronic Pain Drug Market
9. Mental Health Parity Laudable, But House Legislation Would Put Medicaid Patients at Risk, Lilly Says
10. FDA Issues Not-Approvable Letter for Lillys Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
11. Lilly and Partners In Health, Brigham and Womens Hospital Team Up to Fight MDR-TB in Former Soviet Republics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... 2016 , ... W.S. Badger Co. Inc ., the maker of certified ... as one of the best small businesses for new dads by Fatherly, the digital ... businesses providing progressive benefits to new parents on the organization’s 2016 Best Places ...
(Date:5/27/2016)... ... ... This campaign aims to provide a path to improved education and awareness ... change. , As nearly 795,000 Americans suffering from a new or recurrent stoke each ... an estimated 129,000 of these people dying from stroke, it’s become our nation’s fifth-leading ...
(Date:5/27/2016)... Texas (PRWEB) , ... May 27, 2016 , ... ... satisfying Army body fat composition regulations. This is the first time that Coolsculpting ... normally screened at least every six months to ensure they meet the prescribed body-fat ...
(Date:5/27/2016)... ... 2016 , ... Each year Standard Process Inc. ... this year’s Life University winner of a $2,500 scholarship from Standard ... Awards ceremony. , Outerbridge is approaching her last quarter at Life University in ...
(Date:5/26/2016)... ... 26, 2016 , ... There are many ways to cook a hot dog, ... that Americans prefer their dogs straight off the grill. Of the 90 percent of ... way to cook a hot dog, far outpacing other cooking methods such as steaming ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... Amarantus BioScience Holdings, Inc. (OTCQX: AMBS), ... and Orphan Diseases, today announced that President & CEO Gerald ... SeeThru Equity MicroCap Conference   Where: ... , NY When: Tuesday, May 31 st , ... Where: Grand Hyatt Hotel, 109 East 42 nd St, ...
(Date:5/26/2016)... 2016   Change Healthcare , a ... solutions and technology-enabled services designed to enable ... a strategic channel partnership with SourceMed, the ... and revenue cycle management services that empower ... clinics to optimize revenue, operational efficiency and ...
(Date:5/25/2016)... and GERMANTOWN, Maryland , May ... QGEN ; Frankfurt Prime Standard: QIA) today announced that ... with Therawis Diagnostics GmbH to develop and commercialize predictive assays ... market PITX2 as a marker to predict effectiveness of anthracycline ... "We are pleased to partner with Therawis, which ...
Breaking Medicine Technology: